



[Science Archives \(ISSN:2582-6697\)](http://www.sciencearchives.org)

Journal homepage: www.sciencearchives.org



Review Article

<http://dx.doi.org/10.47587/SA.2022.3108>



How do corona (Covid-19) vaccines work? A review

Ekhlas Abdallah Hassan¹, Wafaa Sh. Al – Zuhairi¹✉, Rusul Y. Hameed²

¹Department of Chemistry, College of Science, University of Diyala, Baquba, Diyala, Iraq

²Al hikma College.Unvrsity, Bagdad, Iraq

✉ wafaa.chem@gmail.com

Received: Feb 14, 2022 / Revised: Mar 04, 2022 / Accepted: Mar 12, 2022

Abstract

A safe and effective way to protect against disease is immunization. Where, it aids the body's resistance to some infections and strengthens the immune system, resulting in practicing the system of immune to creating antibodies, specific the ease and speed of the (Covid-19) Coronavirus spread as well majority infection of the humans' population. Vaccine's significance rests in its ability to defend in contradiction of the Covid-19 by promoting the human body to generate a response of an immune. It protects the human body by preventing or controlling the infecting. Vaccines include inactivated parts of a specific organism (antigen) that make the response of immune inside the body. New vaccines contain the scheme to produce the antigen rather than the antigen itself. In any case, whether the vaccine consists of the antigen itself or a scheme that allows producing the antigen inside the body. This attenuated virus is not going to cause disease to people, who have taken the vaccine. However, it will fast the immune system to react as closely as likely as if it were its first response to the actual pathogen. The paper considers the significant advancements in SARS-CoV-2 vaccinations development for humans, with a special focus on the vaccination approach. Furthermore, we would like to learn more about how the current vaccine works, based on previous efforts to offer the vaccine, building on earlier vaccine delivery, to persuade people to get a COVID-19 vaccine in time to stop the pandemic from spreading.

Keywords Covid-19, immunization, Pfizer-Bioentech, Vaccines, Oxford–Astra Zeneca

Introduction

The greatest medical achievements are vaccines in the modern world. It's preventing almost two to three million deaths each year and protect against 20 diseases (Balding, 2006), following World Health Organization (WHO). For example, babyhood diseases, which were commonly less than a generation ago are becoming progressively seldom thanks to vaccines. Where smallpox, which has caused death to millions of people, is been eliminated.

Nonetheless, success often takes decades to achieve. Africa was declared polio-free only last August, nearly 30 years after the start of a global mass vaccination campaign (Hall, 1984). Currently, there are some vaccines of COVID-19 undergoing trials in the clinic. These COVID-19 vaccines will evaluate by U.S. Food and Drug Administration before approving to

utilize. Before the FDA may approve vaccinations for emergency use, researchers must demonstrate that they are both efficacious and safe. But, because the FDA approval process can take from several months to several years, the FDA agreed to provide an emergency use authorization for COVID-19 vaccinations since there is an urgent demand for them. Vaccines are classified based on their mechanism of action. (Razonable et al., 2021).

mRNA vaccine (Pfizer-Bioentech and Moderna vaccine)

The people 16 years of age and older have been 95% effective in preventing the COVID-19 infection of symptoms by The Pfizer-Bioentech vaccine. Also, this vaccine has 100% effective in children aged twelve to fifteen years old in preventing COVID-19. This vaccine is for people 12 years of age and older. Modern's vaccine of Covid-19 is 94 percent

effectual in avoiding symptoms of the virus of Covid-19. The vaccine is only given to those who are at least 18 years old or older (Xie et al., 2021).

The mRNA vaccines have been examined by researchers for sustained periods by sampling standard elements. Scientists can proliferate vaccines in experiential environments and expedite the marketability of these vaccines. Manufacturing

can be modeled according to scientific findings, aiding the expansive process of effective inoculation as opposed to the stagnating courtesy of anachronistic methods (Norbert et al., 2018). Researchers have pinpointed mRNA vaccines for flu, Zika, rabies, and cytomegalovirus (CMV) as pertinent to formulating an inoculation strategy for COVID-19. Cue the introduction of special protein components to strengthen the effectiveness of the mRNA vaccine (Norbert et al., 2018).




Fig. 1 The mechanism of delivery and working of vaccine of mRNA [Park et al., 2021]. mRNA vaccination contains the S protein's coding region. Step 1 is synthesized through IVT, bordered by the optimized 5'- and 3'-UTRs and polyA tail, then 5'-capping with a 5'-cap analogue and encapsulating with LNP for IM injection (Park et al., 2021).

Step 2: Vaccine permeates cells of muscle or antigen cells, thus enabling macrophages via endocytosis or dendritic cells. Step 3, mRNA molecules are channeled from LNPs and metamorphosed to S protein in the ribosome. Recently the synthetic nature of S protein is secreted to create a scenario of extracellular, internalized through endocytosis into antigen-presenting cells.

MHC class II antigen performance complex (steps 5b, 6b, and 7) is used to identify the antigen to immune cells such as T and B cells (Jackson et al., 2020). Proteosomes typically ascribe defective S peptides to MHC class I multiplex, which is next assigned to plasma membranes and expressed as antigens to immune cells (steps 4a, 4b, 5a, and 7).

Messenger RNA (mRNA) features in the COVID-19 vaccines developed by both Pfizer-Bioentek and Moderna. On the surface of Coronavirus infections are spike-shaped entities called the S protein. The COVID-19 vaccines messenger commands RNA-based cells to create an innocuous sector of the virus, namely an S. protein. The cells inevitably emit protein fragments and characterize the cellular profile following inoculation. The immune response

is significantly defined by the proliferation of antibodies and that is contingent upon immune systems' recognition of proteins' corporal intrusions (Centers for Disease Control and Prevention, 2021), Fig.2

DNA vaccines (The Johnson & Johnson and the Oxford–AstraZeneca COVID-19 vaccine)

Double-stranded DNA is used in both the Oxford–AstraZeneca COVID-19 vaccine and the Johnson & Johnson vaccine. Their behavioral patterns signify the interactivity between EUA and FDA determined by stringent clinical trials. This development has not yet reached the US (Knoll et al., 2021). That country's COVID-19 vaccination product is protein-based with an activity index of 89.3%. This does not go on to either mirror or induce COVID-19 (Pimenta et al., 2021).

Human clinical trials using vaccines of DNA for non-viral and catching diseases like hepatitis B, malaria, influenza, HIV, and cancer have since produced unsatisfactory results. (Liu, 2011; Ferraro et al., 2011; Li et al., 2012). The immunogenicity in such cases tends to be less effective than

the results in other mammals. The combination of plasmid DNA into genomic DNA, the danger of autoimmunity, and antigen sufferance have all been successfully pinpointed in the relevant study. It is a case of low responsiveness which corresponds to low immunogenicity. Vaccination of DNA is therefore the prescribed form of inoculation. Understandably, that practice is still advocated for humans if its immunogenicity can be emphasized. In addition to the above stance, DNA vaccines, which have been deemed effective, have been integrated into applications of veterinary since

2005, counting West Nile viruses in horses, canine melanoma, and fish hematopoietic necrosis viruses (Davis et al., 2001; Bergman et al., 2003; Corbeil et al., 1999).

Briefly, a vaccine of DNA consists of introducing elements of genes by using DNA plasmids as vectors. This method serves to encode immunogenic antigens to the cellular profile of the host. Therefore, said method enlivens both humoral and cell-mediated immune responses with desirable efficacy (Silveira et al., 2017; Lee et al., 2018), Fig. 3




Fig. 2 Messenger RNA vaccines get the recipient’s body to produce a viral protein that then stimulates the desired immune response




Fig. 3 The cellular induction and immunity of humoral after immunization with vaccines of DNA

A vaccine of DNA consists of bacteria produced a plasmid which encodes the antigen protein in the presence of the promoter of mammalian. Step 1, Included is the placement of it in a way which it spreads to the nucleus of the cell, allowing transcript and transformation in human transfection cells. Then, the encoded protein from the Vivo uptake plasmid is produced in host cells, the vaccination antigen can

be delivered to antigen-presenting cells (APCs), such as dendritic cells (DCs). Over the MHC pathways, and be given to activate naive T cells. Step 2a, CD8+ T cell immunity is primarily triggered by endogenously produced antigens displayed on MHC class I molecules. The active CD8+ T cell catalyzes the shot of cytokines for example interferon-gamma [IFN- γ] and tumor necrosis factor-alpha [TNF- α] that inhibit

replication of viral and raise the MHC I molecules expression. Step 2b, to support immune responses of cell-mediated macrophages are as well activated to support immune responses or cell-mediated. But step 3, CD4+ T helper cell activation is initiated by MHC class II from APC. Step 4, In case the proteins of the vaccine are concealed, these goals are known through receptors of B cells in naïve B cells, that as well utilize MHC-II to become stimulated. Step 5, in this trial of immune, unlike classes of antibodies (mainly IgG) will be produced by activated B cells to protect versus the illness. Moreover, DNA vaccine immunization expresses cytokines of proinflammatory and chemokines. IL-10, IL-12, and TNF- α , the DCs are responsible for producing it. It stimulates the response of cellular by stimulating CD8+ T cells, and it also activates CD4+ T cells. (Silveira et al., 2021).

An inactivated vaccine

In China, a vaccine with two deactivated SARS-CoV-2 virus applicants developed by the Wuhan Institute of Biological

Products and Sinovac Biotech are now undergoing phase 1 and 2 clinical studies. A complete dead virus (deactivated vaccine) contains virus particles whose duplication has ceased. However, that maintains the efficiency to persuade the reaction of the immune (Pandey et al., 2020).

Fig.4 shows that the inactivated vaccines can be synthesized by counteracting a virus by using radiation of heat or chemicals like β -propiolactone. Live vaccines are not stable without refrigeration in comparing to deactivated vaccines, especially in middle- and low-income countries (LMICs), which has made them available for veterinary use. Waldmann and Köbe developed. Where, in 1938, the first vaccine was contrary to foot and mouth disease. The first vaccine against foot-and-mouth disease in 1938. The researchers utilized viral particles that had been inactivated by formaldehyde. Inactivated viral vaccines are utilized in many influenza seasonal vaccinations given to humans (Lubroth et al., 2007).




Fig. 4 Inactivated vaccines

Predominantly, all dormant viral immunizations conform to the same production program in which first applied is the pathogen on a substrate to multiply certain examples of antigen. Historically, vaccine manufacturer has studied primary cells, tissues, fertilized eggs, and even complete organisms as contagion enhancing agents in respect of the virus (Heinz & Stiasny, 2012). Nowadays, manufacturers of vaccines are faced with virus expansion on consistent cell lines. This is advantageous in production efficiency terms chemical compounds to said process are ascorbic acid (Madhusudana et al., 2004), gamma irradiation (Martin et al., 2010), and others (Stauffer et al., 2006). Nonetheless, the inactivation of licensed human viral vaccines, formaldehyde, and β -Propiolactone (BPL) have been continuously and concertedly applied for decades.

and enhanced safety protocol increased vaccine safety protocol (Barrett et al., 2009). Once the virus has multiplied, it is regularly diluted and subjected to purification and concentration processes before it is duly isolated. This can be accomplished by utilizing physical or chemical approaches or a conflate of the two processes to neutralize the virus. An extensive array of tried and tested inactivation methods or agents have proceeded to successfully isolate viral contagions for vaccinations to be at their most effective levels. Pertinent

A protein subunit

A subunit of protein is a single protein molecule that creates a protein complex with the help of other protein molecules (Li, 2021). Such definitive isolation of a specific protein from

intrusive and invasive agents plus the administering of such a product on its own requires a thorough analysis of protein-based subunits' behavioral patterns. Unnatural and side-lined proteins weaken the aforesaid technique. Taking an antigen's gene from a bacteria or targeted virus and putting it in a virus vector is a second way to make a subunit vaccine (another virus), yeast vector, such as in the case of the hepatitis B attenuated bacterium (bacterial vector) vaccine for the production of a recombination virus or bacteria to render like a serious element of a recombination vaccine (called a recombination subunit vaccine). The antigen will be expressed by the genomically modified recombination vector. The antigen (one or more protein subunits) from the vector is removed. The recombinant-vector-produced antigen, like the component of highly efficient vaccinations, will pose minimal to no risk to the patient. Presently, this kind of vaccine is in utilize for hepatitis B (Marker, 2013). Its existence is widespread in research to find a novel vaccine for strenuous-to-vaccinate-against viruses including HIV and

ebolavirus. (Decker, 2003). Currently, redundant subunits of protein purification with regards to the neutralization of SARS-CoV-2 are being experimented with on humans to expand clinicians' options in battling the virus. Each of these filters employs distinct immunogens, which are essentially different versions of its receptor-binding domain (RBD) or full Spike protein, which is the S protein part that prevents virus-related attachment to the ACE2 target host cells receptor. When S protein binds to the ACE2 receptor's host cell, it undergoes a prefusion adjustment that results in a protracted structural alteration to a very steady post-fusion conformation that allows the viral element to fuse with the host cell's membranes (Hsieh et al., 2021). As is customary, prefusion-stabilized viral glycoproteins are more potent and resistant because they are more linked to the peculiarities of immunogenicity (Sanders et al., 2013) (Crank et al., 2009) (Pallesen et al., 2017). The protein insertion vaccine model is depicted in Fig. 5.




Fig. 5 Vaccines subunit are all set either from recombinant antigens expressed or from purification antigens of pathogens replicated in cell cultures. Commonly, these vaccines seek adjuvant addendum to transport risk signals to cells of antigen-presenting and induce strong responses of the immune (Kyriakidis et al., 2021)

Conclusions

Vaccination is seen as the bedrock of maintaining health and immunity to diseases and viruses as scientists combat existing and potential pandemics. Previous efforts in the evaluation of vaccine (live weakened, deactivated, vector-based, subunit-based of protein, and DNA-based), and attack of other viruses, which includes MERS and SARS, have facilitated the development of COVID-19. Herd immunity cannot be established without the uncompromising controls imposed on societies to stifle the spread of the virus. Such draconian controls should be enforced in conjunction with

meticulous vaccination roll-outs throughout the world as COVID-19 variants emerge and defy current findings. Therefore, scientists (microbiologists and immunologists alike) will be forced to be supremely diligent and circumspect as vaccine mixing and potentially harmful resultant interactivity may scupper the hard-earned confidence in the advancement of immunology. COVID-19 will require a more structured strategic immunogenic approach than has hitherto been expected.

Conflict of Interest

The author hereby declares no conflict of interest.

References

- Balding, B. (2006). Mandatory vaccination: why we still got to get folks to take their shots.
- Barrett, P. N., Mundt, W., Kistner, O., & Howard, M. K. (2009). Vero cell platform in vaccine production: moving towards cell culture-based viral vaccines. *Expert review of vaccines*, 8(5), 607-618.
- Bergman, P. J., McKnight, J., Novosad, A., Charney, S., Farrelly, J., Craft, D., & Wolchok, J. D. (2003). Long-term survival of dogs with advanced malignant melanoma after DNA vaccination with xenogeneic human tyrosinase: a phase I trial. *Clinical Cancer Research*, 9(4), 1284-1290.
- Centers for Disease Control and Prevention. (2021). Information about COVID-19 vaccines for people with allergies.
- Corbeil, S., LaPatra, S. E., Anderson, E. D., Jones, J., Vincent, B., Hsu, Y. L., & Kurath, G. (1999). Evaluation of the protective immunogenicity of the N, P, M, NV and G proteins of infectious hematopoietic necrosis virus in rainbow trout *Oncorhynchus mykiss* using DNA vaccines. *Diseases of Aquatic Organisms*, 39(1), 29-36.
- Crank, M. C., Ruckwardt, T. J., Chen, M., Morabito, K. M., Phung, E., Costner, P. J., & VRC 317 Study Team. (2019). A proof of concept for structure-based vaccine design targeting RSV in humans. *Science*, 365(6452), 505-509.
- Davis, B. S., Chang, G. J. J., Cropp, B., Roehrig, J. T., Martin, D. A., Mitchell, C. J., ... & Bunning, M. L. (2001). West Nile virus recombinant DNA vaccine protects mouse and horse from virus challenge and expresses in vitro a noninfectious recombinant antigen that can be used in enzyme-linked immunosorbent assays. *Journal of virology*, 75(9), 4040-4047.
- Decker, J. M. "Vaccines". Immunology Course 419. Department of Veterinary Science & Microbiology at The University of Arizona. Archived from the original on 2003-06-10.
- Ferraro, B., Morrow, M. P., Hutnick, N. A., Shin, T. H., Lucke, C. E., & Weiner, D. B. (2011). Clinical applications of DNA vaccines: current progress. *Clinical infectious diseases*, 53(3), 296-302.
- Hall, S. (1984). The narrative construction of reality: an interview with Stuart Hall.-Reprinted from a transcript of an interview by John O'Hara on the ABC programme 'Double Take', 5 May 1983. *Southern Review (Adelaide)*, 17(1), 3-17
- Heinz, F. X., & Stiasny, K. (2012). Flaviviruses and flavivirus vaccines. *Vaccine*, 30(29), 4301-4306.
- Hsieh, C. L., Goldsmith, J. A., Schaub, J. M., DiVenere, A. M., Kuo, H. C., Javanmardi, K., ... & McLellan, J. S. (2020). Structure-based design of prefusion-stabilized SARS-CoV-2 spikes. *Science*, 369(6510), 1501-1505.
- Jackson, N. A., Kester, K. E., Casimiro, D., Gurunathan, S., & DeRosa, F. (2020). The promise of mRNA vaccines: a biotech and industrial perspective. *npj Vaccines*, 5(1), 1-6.
- Knoll, M. D., & Wonodi, C. (2021). Oxford–AstraZeneca COVID-19 vaccine efficacy. *The Lancet*, 397(10269), 72-74.
- Kyriakidis, N. C., López-Cortés, A., González, E. V., Grimaldos, A. B., & Prado, E. O. (2021). SARS-CoV-2 vaccines strategies: a comprehensive review of phase 3 candidates. *npj Vaccines*, 6(1), 1-17.
- Lee, L. Y. Y., Izzard, L., & Hurt, A. C. (2018). A review of DNA vaccines against influenza. *Frontiers in immunology*, 9, 1568.
- Li, L., Saade, F., & Petrovsky, N. (2012). The future of human DNA vaccines. *Journal of biotechnology*, 162(2-3), 171-182.
- Li, Y., Liang, S., & Ng, C. W. (2021). A comprehensive comparison between COVID-19 vaccines: a review. *ScienceOpen Preprints*.
- Liu, M. A. (2011). DNA vaccines: an historical perspective and view to the future. *Immunological reviews*, 239(1), 62-84.
- Lubroth, J., Rweyemamu, M. M., Viljoen, G., Diallo, A., Dungu, B., & Amanfu, W. (2007). Veterinary vaccines and their use in developing countries. *Revue scientifique et technique (International Office of Epizootics)*, 26(1), 179-201.
- Madhusudana, S. N., Shamsundar, R., & Seetharaman, S. (2004). In vitro inactivation of the rabies virus by ascorbic acid. *International journal of infectious diseases*, 8(1), 21-25.
- Marker, S. (2013). hepatitis B virus infection I. *CDC Health Information for International Travel 2014: The Yellow Book*, 186.
- Martin, S. S., Bakken, R. R., Lind, C. M., Garcia, P., Jenkins, E., Glass, P. J., & Fine, D. L. (2010). Comparison of the immunological responses and efficacy of gamma-irradiated V3526 vaccine formulations against subcutaneous and aerosol challenge with Venezuelan equine encephalitis virus subtype IAB. *Vaccine*, 28(4), 1031-1040.
- Norbert, P., Michael, J. H., Frederick, W. P., & Drew, W. (2018). mRNA vaccines—A new era in vaccinology. *Nat. Rev. Drug Discov*, 17(4), 261-279.
- Pallesen, J., Wang, N., Corbett, K. S., Wrapp, D., Kirchdoerfer, R. N., Turner, H. L., & McLellan, J. S. (2017). Immunogenicity and structures of a rationally designed prefusion MERS-CoV spike antigen. *Proceedings of the National Academy of Sciences*, 114(35), E7348-E7357.
- Pandey, S. C., Pande, V., Sati, D., Upreti, S., & Samant, M. (2020). Vaccination strategies to combat novel corona virus SARS-CoV-2. *Life sciences*, 256, 117956.
- Park, J. W., Lagniton, P. N., Liu, Y., & Xu, R. H. (2021). mRNA vaccines for COVID-19: what, why and how. *International journal of biological sciences*, 17(6), 1446.
- Pimenta, D., Yates, C., Pagel, C., & Gurdasani, D. (2021). Delaying the second dose of covid-19 vaccines. *bmj*, 372.
- Razonable, R. R., Aloia, N. C., Anderson, R. J., Anil, G., Arndt, L. L., Arndt, R. F., ... & Borgen, M. J. D. (2021, May). A framework for outpatient infusion of antispike monoclonal antibodies to high-risk patients with mild-to-moderate coronavirus disease-19: the Mayo Clinic Model. *In Mayo Clinic Proceedings* (Vol. 96, No. 5, pp. 1250-1261). Elsevier.
- Sanders, R. W., Derking, R., Cupo, A., Julien, J. P., Yasmeen, A., de Val, N., & Moore, J. P. (2013). A next-generation cleaved, soluble HIV-1 Env trimer, BG505 SOSIP.664 gp140, expresses multiple epitopes for broadly neutralizing but not non-neutralizing antibodies. *PLoS pathogens*, 9(9), e1003618.
- Silveira, M. M., Moreira, G. M. S. G., & Mendonça, M. (2021). DNA vaccines against COVID-19: Perspectives and challenges. *Life sciences*, 267, 118919.
- Silveira, M. M., Oliveira, T. L., Schuch, R. A., McBride, A. J. A., Dellagostin, O. A., & Hartwig, D. D. (2017). DNA vaccines against leptospirosis: A literature review. *Vaccine*, 35(42), 5559-5567.
- Stauffer, F., El-Bacha, T., & Da Poian, A. T. (2006). Advances in the development of inactivated virus vaccines. *Recent patents on anti-infective drug discovery*, 1(3), 291-296.
- Xie, X., Zou, J., Fontes-Garfias, C. R., Xia, H., Swanson, K. A., Cutler, M., & Dormitzer, P. R. (2021). Neutralization of N501Y Mutant SARS-CoV-2 by BNT162b2 Vaccine-Elicited Sera. *bioRxiv Prepr. Serv. Biol.*

How to cite this article

Hassan I, E. A., Al-Zuhairi, W. S., Hameed, R. Y. (2022). How do corona (Covid-19) vaccines work? A Review. *Science Archives*, Vol. 3 (1), 66-71.

<http://dx.doi.org/10.47587/SA.2022.3108>

This work is licensed under a [Creative Commons Attribution 4.0 International License](https://creativecommons.org/licenses/by/4.0/)



Publisher's Note: MD International Publishing stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.